A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma
Year: 2015
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Thomas Martin, Joshua Richter, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey Zonder, Jonathan L. Kaufman, William Bensinger, Meletios A. Dimopoulos, Jesús San Miguel, Todd Zimmerman, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Karl Hsu, Eric Charpentier, Stephen A. Strickland, Joseph Mikhael
Institutions: University of California, San Francisco, Hackensack University Medical Center, Washington University in St. Louis, University of Michigan, U-M Rogel Cancer Center, Huntsman Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Winship Cancer Institute, Fred Hutch Cancer Center, National and Kapodistrian University of Athens, Universidad de Navarra, University of Chicago, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, Duke Medical Center, Mayo Clinic, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Mayo Clinic in Arizona
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2529484267